Mesirow Institutional Investment Management Inc. Invests $10.84 Million in Alkermes plc (NASDAQ:ALKS)

Mesirow Institutional Investment Management Inc. purchased a new position in Alkermes plc (NASDAQ:ALKS - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 376,867 shares of the company's stock, valued at approximately $10,839,000. Mesirow Institutional Investment Management Inc. owned about 0.23% of Alkermes as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also recently bought and sold shares of ALKS. Venturi Wealth Management LLC acquired a new stake in shares of Alkermes during the fourth quarter worth approximately $25,000. EverSource Wealth Advisors LLC grew its stake in Alkermes by 106.2% in the 4th quarter. EverSource Wealth Advisors LLC now owns 1,635 shares of the company's stock valued at $47,000 after buying an additional 842 shares during the last quarter. Blue Trust Inc. boosted its holdings in Alkermes by 2,231.5% during the fourth quarter. Blue Trust Inc. now owns 1,702 shares of the company's stock valued at $49,000 after acquiring an additional 1,629 shares during the period. Smartleaf Asset Management LLC grew its position in shares of Alkermes by 558.5% in the fourth quarter. Smartleaf Asset Management LLC now owns 2,950 shares of the company's stock valued at $85,000 after purchasing an additional 2,502 shares during the last quarter. Finally, Cornerstone Investment Partners LLC bought a new position in shares of Alkermes in the fourth quarter worth about $203,000. Institutional investors and hedge funds own 95.21% of the company's stock.

Insider Buying and Selling at Alkermes

In related news, EVP Craig C. Hopkinson sold 144,419 shares of the stock in a transaction that occurred on Thursday, February 13th. The shares were sold at an average price of $35.53, for a total transaction of $5,131,207.07. Following the sale, the executive vice president now owns 57,875 shares in the company, valued at approximately $2,056,298.75. This trade represents a 71.39 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 4.89% of the company's stock.

Alkermes Price Performance

Shares of Alkermes stock traded up $0.16 on Friday, hitting $27.83. The company had a trading volume of 562,131 shares, compared to its average volume of 1,752,176. The firm has a market capitalization of $4.59 billion, a P/E ratio of 12.80, a P/E/G ratio of 2.20 and a beta of 0.39. Alkermes plc has a twelve month low of $22.90 and a twelve month high of $36.45. The stock has a 50-day moving average of $32.08 and a 200-day moving average of $30.38.

Alkermes (NASDAQ:ALKS - Get Free Report) last released its earnings results on Wednesday, February 12th. The company reported $0.92 earnings per share for the quarter, beating analysts' consensus estimates of $0.81 by $0.11. Alkermes had a net margin of 23.57% and a return on equity of 30.80%. Equities analysts predict that Alkermes plc will post 1.31 EPS for the current year.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the company. UBS Group raised Alkermes from a "sell" rating to a "neutral" rating and lifted their target price for the stock from $21.00 to $38.00 in a research report on Tuesday, March 4th. Deutsche Bank Aktiengesellschaft lifted their target price on shares of Alkermes from $40.00 to $52.00 and gave the company a "buy" rating in a research report on Thursday, March 27th. StockNews.com raised Alkermes from a "buy" rating to a "strong-buy" rating in a report on Thursday, February 13th. Royal Bank of Canada assumed coverage on Alkermes in a research report on Thursday, March 13th. They issued a "sector perform" rating and a $40.00 price target on the stock. Finally, HC Wainwright reissued a "neutral" rating and set a $46.00 price objective on shares of Alkermes in a report on Thursday, February 13th. Four equities research analysts have rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, Alkermes presently has a consensus rating of "Moderate Buy" and a consensus target price of $38.50.

Alkermes Company Profile

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.